Optibrium widens access to industry-leading docking method

Optibrium, a leading developer of software and AI solutions for molecular design today announced the introduction of a new PyMOL Graphical User Interface (GUI) for Surflex-Dock, its industry-leading structure-based design method, which is part of the company’s BioPharmics 3D molecular modelling suite.

Perimenopausal women face increased risk of depression and mania, study reveals

Explore why women may be at higher risk of developing mania and major depressive disorder during perimenopause.

August 19, 2024

Eli Lilly settles with medical spa over its marketing of compounded tirzepatide

Eli Lilly reached a settlement with a South Carolina medical spa, marking a win in a broader legal campaign against how compounders have marketed versions

May 16, 2024

Adding Tirzepatide to Basal Insulin Cuts HbA1c in Poorly Controlled T2D

HAMBURG, Germany — Adding weekly tirzepatide (Mounjaro) to basal insulin reduced HbA1c in patients with poorly controlled type 2 diabetes compared with adding three-times-daily insulin

October 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.